Regulation of MHC class II expression in human T-cell malignancies

Blood

Volumn 103, Issue 4, 2004, Pages 1438-1444

  Holling, Tjadine M ^b   Schooten, Erik ^b   Langerak, Anton W ^b   Van Den Elsen, Peter J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CYCLIC AMP; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSCRIPTION FACTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DNA RESPONSIVE ELEMENT; EPIGENETICS; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOREGULATION; IN VITRO STUDY; LEUKEMIA CELL LINE; LYMPHOMA CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LEUKEMIA; T LYMPHOCYTE ACTIVATION;

EID: 0842328824     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-05-1491     Document Type: Article

References (52)

1. Ferrando AA, Look AT. Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia. Semin Hematol. 2000;37:381-395.
2. Ferrando AA, Neuberg DS, Stauton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1:75-87.
3. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991;66:649-661.
4. Marriott SJ, Lemoine FJ, Jeang KT. Damaged DNA and miscounted chromosomes: human T cell leukemia virus type I tax oncoprotein and genetic lesions in transformed cells. J Biomed Sci. 2002;9:292-298.
5. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211-1218.
6. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90: German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95:3310-3322.
7. Hoelzer D, Gokbuget N. New approaches to acute lymphoblastic leukemia in adults: where do we go? Semin Oncol. 2000;27:540-559.
8. Garand R, Vannier JP, Bene MC, Faure G, Favre M, Bernard A. Comparison of outcome, clinical, laboratory, and immunological features in 164 children and adults with T-ALL: The Groupe d'Etude Immunologique des Leucemies. Leukemia. 1990;4:739-744.
9. Delain M, Tiberghien P, Racadot E, et al. Variability of the alloreactive T-cell response to human leukemic blasts. Leukemia. 1994;8:642-647.
10. Nagy ZA, Hubner B, Lohning C, et al. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med. 2002;8:801-807.
11. Lo Coco F. Hybrid phenotypes and lineage promiscuity in acute leukemia. Haematologica. 1991;76:215-225.
12. Lanzavecchia A, Roosnek E, Gregory T, Berman P, Abrignani S. T cells can present antigens such as HIV gp120 targeted to their own surface molecules. Nature. 1988;334:530-532.
13. Hewitt CR, Feldmann M. Human T cell clones present antigen. J Immunol. 1989;143:762-769.
14. Siliciano RF, Lawton T, Knall C, et al. Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: effect of HIV sequence variation and a mechanism for CD4+ cell depletion. Cell. 1988;54:561-575.
15. Wyss-Coray T, Brander C, Bettens F, Mijic D, Pichler WJ. Use of antibody/peptide constructs of direct antigenic peptides to T cells: evidence for T cell processing and presentation. Cell Immunol. 1992;139:268-273.
16. Wyss-Coray T, Brander C, Frutig K, Pichfer WJ. Discrimination of human CD4 T cell clones based on their reactivity with antigen-presenting T cells. Eur J Immunol. 1992;22:2295-2302.
17. LaSalle JM, Ota K, Hafler DA. Presentation of autoantigen by human T cells. J Immunol. 1991;147:774-780.
18. Barnaba V, Watts C, de Boer M, Lane P, Lanzavecchia A. Professional presentation of antigen by activated human T cells. Eur J Immunol. 1994;24:71-75.
19. Pichler WJ, Wyss-Coray T. T cells as antigen-presenting cells. Immunol Today. 1994;15:312-315.
20. Nakada M, Nishizaki K, Yoshino T, et al. CD80 (B7-1) and CD86 (B7-2) antigens on house dust mite-specific T cells in atopic disease function through T-T cell interactions. J Allergy Clin Immunol. 1999;104:222-227.
21. Di Rosa F, D'Oro U, Ruggiero G, et al. HLA class II molecules transduce accessory signals affecting the CD3 but not the interleukin-2 activation pathway in T blasts. Hum Immunol. 1993;38:251-260.
22. Kudo H, Matsuoka T, Mitsuya H, Nishimura Y, Matsushita S. Cross-linking HLA-DR molecules on Th1 cells induces anergy in association with increased level of cyclin-dependent kinase inhibitor p27(Kip1). Immunol Lett. 2002;81:149-155.
23. Reith W, Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol. 2001;19:331-373.
24. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. 1997;16:2851-2860.
25. Muhlethaler-Mottet A, Di Berardino W, Otten LA, Mach B. Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Statl and USF-1. Immunity. 1998;8:157-166.
26. Piskurich JF, Wang Y, Linhoff MW, White LC, Ting JP. Identification of distinct regions of 5′ flanking DNA that mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of the class II transactivator gene. J Immunol. 1998;160:233-240.
27. Piskurich JF, Linhoff MW, Wang Y, Ting JP. Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta. Mol Cell Biol. 1999;19:431-440.
28. Van der Stoep N, Quinten E, van den Elsen PJ. Transcriptional regulation of the MHC class II trans-activator (CIITA) promoter III: identification of a novel regulatory region in the 5′-untranslated region and an important role for cAMP-responsive element binding protein 1 and activating transcription factor-1 in CIITA-promoter III transcriptional activation in B lymphocytes. J Immunol. 2002;169:5061-5071.
29. Holling TM, van der Stoep N, Quinten E, van den Elsen PJ. Activated human T cells accomplish MHC class II expression through T cell specific occupation of class II transactivator promoter III. J Immunol. 2002;168:763-770.
30. Wong AW, Ghosh N, McKinnin KP, et al. Regulation and specificity of MHC2TA promoter usage in human primary T lymphocytes and cell line. J Immunol. 2002;169:3112-3119.
31. Van Dongen JJ, Krissansen GW, Wolvers-Tettero IL, et al. Cytoplasmic expression of the CD3 antigen as a diagnostic marker for immature T-cell malignancies. Blood. 1988;71:603-612.
32. Langerak AW, Wolvers-Tettero IL, van den Beemd MW, et al. Immunophenotypic and immunogenotypic characteristics of TCRgammadelta+ T cell acute lymphoblastic leukemia. Leukemia. 1999;13:206-214.
33. Langerak AW, van den Beemd R, Wolvers-Tettero, et al. Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalpha-beta T-cell proliferations. Blood. 2001;98:165-173.
34. Vandekerckhove BAE, Datema G, Koning F, et al. Analysis of the donor-specific cytotoxic T lymphocyte repertoire in a patient with a long term surviving allograft. J Immunol. 1990;144:1288-1294.
35. Van den Elsen PJ, van der Stoep N, Viëtor HE, Wilson L, van Zutphen M, Gobin SJP. Lack of CIITA expression is central to the absence of antigen presentation functions of trophoblast cells and is caused by methylation of the IFNγ inducible promoter (PIV) of CIITA. Hum Immunol. 2000;61:850-862.
36. Peijnenburg A, Godthelp B, van Boxel-Dezaire A, van den Elsen PJ. Definition of a novel complementation group in MHC class II deficiency. Immunogenetics. 1995;41:287-294.
37. Brenner CA, Tam AW, Nelson PA, et al. Message amplification phenotyping (MAPPing): a technique to simultaneously measure multiple mRNAs from small numbers of cells. Biotechniques. 1989;7:1096-1103.
38. Keshet I, Lieman-Hurwitz J, Cedar H. DNA methylation affects the formation of active chromatin. Cell. 1986;44:535-543.
39. Van der Stoep N, Biesta P, Quinten E, van den Elsen PJ. Lack of IFN-gamma-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines. Int J Cancer. 2002;97:501-507.
40. Saufuddin M, Roebuck KA, Chang CH, Ting Y-P, Spear GT. Cutting edge: activation of HIV-1 transcription by the MHC class II transactivator. J Immunol. 2000;164:3941-3945.
41. Murphy K, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol. 2002;2:933-944.
42. Wilson CB, Makar KW, Perez-Melgosa M. Epigenetic regulation of T cell fate and function. J Infect Dis. 2002;185:S37-S45.
43. Morris AC, Spangler WE, Boss JM. Methylation of class II trans-activator promoter IV: a novel mechanism of MHC class II gene control. J Immunol. 2000;164:4143-4149.
44. Cunliffe VT. Memory by modification: the influence of chromatin structure on gene expression during vertebrate development. Gene. 2003;305:141-150.
45. Reik W, Santos F, Dean W. Mammalian epigenomics: reprogramming the genome for development and therapy. Theriogenology. 2003;59:21-32.
46. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet. 2002;3:662-673.
47. Melki JR, Clark SJ. DNA methylation changes in leukaemia. Semin Cancer Biol. 2002;12:347-357.
48. Nephew KP, Huang TH. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett. 2003;190:125-133.
49. Oka T, Ouchida M, Koyama M, et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res. 2002;62:6390-6394.
50. Salvatore P, Benvenuto G, Pero R, Lembo F, Bruni CB, Chiariotti L. Galectin-1 gene expression and methylation state in human T leukemia cell lines. Int J Oncol. 2000;17:1015-1018.
51. Watt PM, Kumar R, Kees UR. Promoter demethylation accompanies reactivation of the HOX11 proto-oncogene in leukemia. Genes Chromosomes Cancer. 2000;29:371-377.
52. Hofmann WK, Tsukasaki K, Takeuchi N, Takeuchi S, Koeffler HP. Methylation analysis of cell cycle control genes in adult T-cell leukemia/lymphoma. Leuk Lymphoma. 2001;42:1107-1109.